Exact Sciences Corporation (EXAS)
Stock Price:
$85.33 USD
-1.87 (-2.14%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
12.81B |
| Revenue (ttm) |
1.13B |
| Net Income (ttm) |
-154.35M |
| Shares Out |
150.17M |
| EPS (ttm) |
-1.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$85.33 |
| Previous Close |
$87.20 |
| Change ($) |
-1.87 |
| Change (%) |
-2.14% |
| Day's Open |
86.86 |
| Day's Range |
84.88 - 87.36 |
| Day's Volume |
652,622 |
| 52-Week Range |
35.25 - 123.31 |
More Stats
| Market Cap |
12.81B |
| Enterprise Value |
13.29B |
| Earnings Date (est) |
Nov 3, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
150.17M |
| Float |
148.22M |
| EPS (basic) |
-0.98 |
| EPS (diluted) |
-1.09 |
| FCF / Share |
-1.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
13.30M |
| Short Ratio |
10.67 |
| Short % of Float |
9.91% |
| Beta |
1.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
11.33 |
| PB Ratio |
5.21 |
| Revenue |
1.13B |
| Operating Income |
-281.15M |
| Net Income |
-154.35M |
| Free Cash Flow |
-239.89M |
| Net Cash |
-472.49M |
| Net Cash / Share |
-3.15 |
| Gross Margin |
58.31% |
| Operating Margin |
-24.86% |
| Profit Margin |
-13.60% |
| FCF Margin |
-21.21% |
| ROA |
-4.84% |
| ROE |
-9.42% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (15)
| Buy |
14 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$116.50*
(36.53% upside)
Low
107
Current: $85.33
High
135
Target: 116.50
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 876 | 454 | 266 | 99.38 | 39.44 | 1.80 | 4.14 | 4.14 | 4.16 | 5.34 |
| Revenue Growth | 92.82% | 70.86% | 167.66% | 151.99% | 2093.38% | -56.61% | 0% | -0.46% | -22.1% | - |
| Gross Profit | 660 | 338 | 188 | 54.18 | 14.94 | -2.53 | 4.14 | 4.14 | 4.14 | 5.32 |
| Operating Income | -234 | -159 | -118 | -169 | -159 | -101 | -46.76 | -52.64 | -28.82 | -11.83 |
| Net Income | -83.99 | -175 | -114 | -167 | -158 | -100 | -46.51 | -52.42 | -28.68 | -11.56 |
| Shares Outstanding | 131 | 122 | 116 | 102 | 92.14 | 80.23 | 67.49 | 59.48 | 52.51 | 40.46 |
| Earnings Per Share | -0.64 | -1.43 | -0.99 | -1.63 | -1.71 | -1.25 | -0.69 | -0.88 | -0.54 | -0.29 |
| Operating Cash Flow | -115 | -69.33 | -71.72 | -130 | -134 | -81.46 | -40.28 | -44.52 | -27.46 | -13.44 |
| Capital Expenditures | -172 | -150 | -48.48 | -14.85 | -21.98 | -11.99 | -8.75 | -0.68 | -2.12 | -0.63 |
| Free Cash Flow | -287 | -219 | -120 | -145 | -156 | -93.45 | -49.03 | -45.20 | -29.58 | -14.07 |
| Cash & Equivalents | 324 | 1,124 | 425 | 311 | 307 | 283 | 133 | 108 | 93.36 | 95.42 |
| Total Debt | 955 | 689 | 4.45 | 4.81 | 4.96 | 1.36 | 1.71 | 2.04 | 1.00 | 1.00 |
| Net Cash / Debt | -631 | 435 | 420 | 306 | 302 | 281 | 132 | 106 | 92.36 | 94.42 |
| Assets | 3,506 | 1,524 | 599 | 377 | 364 | 313 | 147 | 112 | 96.95 | 96.52 |
| Liabilities | 1,218 | 843 | 78.14 | 41.75 | 37.17 | 23.84 | 11.31 | 13.52 | 13.46 | 16.76 |
| Book Value | 2,288 | 681 | 520 | 335 | 327 | 289 | 135 | 98.60 | 83.50 | 79.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Exact Sciences Corporation |
| Country |
United States |
| Employees |
4,110 |
| CEO |
Kevin T. Conroy |
Stock Information
| Ticker Symbol |
EXAS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: EXAS |
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.